136 related articles for article (PubMed ID: 15108188)
41. CYP2D6 basic genotyping as a potential tool to improve the antiemetic efficacy of ondansetron in prophylaxis of postoperative nausea and vomiting.
Niewiński PA; Wojciechowski R; Śliwiński M; Hurkacz ME; Głowacka K; Orzechowska-Juzwenko K; Wiela-Hojeńska AK
Adv Clin Exp Med; 2018 Nov; 27(11):1499-1503. PubMed ID: 30058787
[TBL] [Abstract][Full Text] [Related]
42. Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia.
Zwisler ST; Enggaard TP; Mikkelsen S; Brosen K; Sindrup SH
Acta Anaesthesiol Scand; 2010 Feb; 54(2):232-40. PubMed ID: 19719813
[TBL] [Abstract][Full Text] [Related]
43. The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population.
Halling J; Weihe P; Brosen K
Br J Clin Pharmacol; 2008 Jan; 65(1):134-8. PubMed ID: 17764479
[TBL] [Abstract][Full Text] [Related]
44. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.
Sachse C; Brockmöller J; Bauer S; Roots I
Am J Hum Genet; 1997 Feb; 60(2):284-95. PubMed ID: 9012401
[TBL] [Abstract][Full Text] [Related]
45. The effects of tramadol on static and dynamic pupillometry in healthy subjects--the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status.
Fliegert F; Kurth B; Göhler K
Eur J Clin Pharmacol; 2005 Jun; 61(4):257-66. PubMed ID: 15906019
[TBL] [Abstract][Full Text] [Related]
46. Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status.
Barclay ML; Sawyers SM; Begg EJ; Zhang M; Roberts RL; Kennedy MA; Elliott JM
Pharmacogenetics; 2003 Oct; 13(10):627-32. PubMed ID: 14515061
[TBL] [Abstract][Full Text] [Related]
47. Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study.
Tamminga WJ; Wemer J; Oosterhuis B; de Boer A; Vranckx S; Drenth BF; de Zeeuw RA; de Leij LF; Jonkman JH
Eur J Clin Pharmacol; 2003 May; 59(1):57-64. PubMed ID: 12743673
[TBL] [Abstract][Full Text] [Related]
48. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
[TBL] [Abstract][Full Text] [Related]
49. Association between cytochrome P450 (CYP) 2C19 polymorphisms and harm avoidance in Japanese.
Yasui-Furukori N; Kaneda A; Iwashima K; Saito M; Nakagami T; Tsuchimine S; Kaneko S
Am J Med Genet B Neuropsychiatr Genet; 2007 Sep; 144B(6):724-7. PubMed ID: 17357148
[TBL] [Abstract][Full Text] [Related]
50. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
Neafsey P; Ginsberg G; Hattis D; Sonawane B
J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
[TBL] [Abstract][Full Text] [Related]
51. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.
Wuttke H; Rau T; Heide R; Bergmann K; Böhm M; Weil J; Werner D; Eschenhagen T
Clin Pharmacol Ther; 2002 Oct; 72(4):429-37. PubMed ID: 12386645
[TBL] [Abstract][Full Text] [Related]
52. The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine.
Gross AS; Phillips AC; Rieutord A; Shenfield GM
Br J Clin Pharmacol; 1996 Apr; 41(4):311-7. PubMed ID: 8730977
[TBL] [Abstract][Full Text] [Related]
53. Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes.
Vandel P; Haffen E; Vandel S; Bonin B; Nezelof S; Sechter D; Broly F; Bizouard P; Dalery J
Eur J Clin Pharmacol; 1999 Nov; 55(9):659-65. PubMed ID: 10638395
[TBL] [Abstract][Full Text] [Related]
54. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Zanger UM; Raimundo S; Eichelbaum M
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):23-37. PubMed ID: 14618296
[TBL] [Abstract][Full Text] [Related]
55. Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers.
Novalbos J; López-Rodríguez R; Román M; Gallego-Sandín S; Ochoa D; Abad-Santos F
J Clin Psychopharmacol; 2010 Oct; 30(5):504-11. PubMed ID: 20814331
[TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
57. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?
Dorne JL; Walton K; Slob W; Renwick AG
Food Chem Toxicol; 2002 Nov; 40(11):1633-56. PubMed ID: 12176090
[TBL] [Abstract][Full Text] [Related]
58. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.
VanderVaart S; Berger H; Sistonen J; Madadi P; Matok I; Gijsen VM; de Wildt SN; Taddio A; Ross CJ; Carleton BC; Hayden MR; Koren G
Ther Drug Monit; 2011 Aug; 33(4):425-32. PubMed ID: 21743374
[TBL] [Abstract][Full Text] [Related]
59. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
Preskorn SH; Nichols AI; Paul J; Patroneva AL; Helzner EC; Guico-Pabia CJ
J Psychiatr Pract; 2008 Nov; 14(6):368-78. PubMed ID: 19057238
[TBL] [Abstract][Full Text] [Related]
60. Genotype and phenotype of cytochrome P450 2D6 in human immunodeficiency virus-positive patients and patients with acquired immunodeficiency syndrome.
O'Neil WM; Gilfix BM; Markoglou N; Di Girolamo A; Tsoukas CM; Wainer IW
Eur J Clin Pharmacol; 2000 Jun; 56(3):231-40. PubMed ID: 10952478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]